Background: Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …

Responding to the coronavirus disease 2019 (COVID-19) pandemic has been an
unexpected and unprecedented global challenge for humanity in this century. During this …

To assess the clinical efficacy and safety of neutralizing monoclonal antibodies (mABs) for
outpatients with coronavirus disease 2019 (COVID‐19). PubMed, Embase, Web of Science …

Background Some patients with systemic autoimmune rheumatic disease and
immunosuppression might still be at risk of severe COVID-19. The effect of outpatient SARS …

Decoy receptor proteins that trick viruses to bind to them should be resistant to viral escape
because viruses that require entry receptors cannot help but bind decoy receptors …

The COVID‐19 pandemic has caused an unprecedented health crisis and economic burden
worldwide. Its etiological agent SARS‐CoV‐2, a new virus in the coronavirus family, has …

The respiratory system, especially the lung, is the key site of pathological injury induced by
SARS-CoV-2 infection. Given the low feasibility of targeted delivery of antibodies into the …

Importance Evidence on the effectiveness and safety of COVID-19 therapies across a
diverse population with varied risk factors is needed to inform clinical practice. Objective To …

Background: Numerous tools, including inflammatory biomarkers and lung injury severity
scores, have been evaluated as predictors of disease progression and the requirement for …

Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in
1986, 165 antibody drugs have been approved or are under regulatory review worldwide …